Naslov
Sertraline in the therapy of psychiatric patients

Autori
Folnegović-Šmalc, Vera ; Mimica, Ninoslav ; Uzun, Suzana ; Ljubin, Tajana ; Markan-Šošić, Vera

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Periodicum biologorum 103 (Suppl. 1) / Vitale, Branko - Zagreb : Periodicum biologorum, Hrvatsko prirodoslovno društvo, 2001, 107-107

Skup
Third Croatian Congress of Pharmacology With International Participation

Mjesto i datum
Zagreb, Hrvatska, 18.09.2001. - 21.09.2001

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
sertraline; psychiatric treatment

Sažetak
Sertraline, a naphtylamine derivative is a new, structurallyunique antidepressant for oral administration. The mechanism of action of sertraline is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin (5HT). Studies at clinically relevant doses in man have demonstarted that sertraline blocks the uptake of serotonin into human platelets. In man, folowing oral onec-daily dosing over the range of 50 to 200 mg per for 14 days, mean peak plasma concentration of setraline occured between 4.5 to 8.4 hours post-dosing. The average terminal elimination half-life of plasma sertraline is about 26 hours. based on this pharmacokinetic parametar, steady-state sertraline plasma levels should be achived after approximately one week of once-daily dosing. The efficacy of sertraline for the tretment of the patients with depression was evalueted in total of 15 studies included 1451 setraline, 491 placebo and 288 amitriptylinetreated patients. Efficacy scales in all studies including the Hamilton Rateing Scale for Depression (HAMD), Clinical Global Impresion (CGI) and self-rating scale. The efficacy database for treatment of acute depression included a total of 5 placebo-controlled studies. On these, the two largest studies (each including over 350 patients) prove the antidepressant efficacy of sertraline. Sertraline has been administrated to 1568 subjects and has been genrally well tolareted. There is adequate long-longsafety experience (111 patients treted for 52 weeks or more) for a drug of this class. Sertraline is neither sedative nor stimulant over the therapeutic dose rnage of 50-200mg/day, compared with the well recognised sedative properties of the tricyclic antidepressants. In addition, sertraline does not have anticholinergic or cardiotoxic properties, again unlike the tricyclic antidepressants.Sertraline is not associated with weight gain during therapy. In overdosage sertraline may be safer than the tricyclic or MAOI antidepressants, and sertraline was not associated with the developemnt of dependence. Other beneficial properties of sertraline are once a day dosing to aid compliance, a pharmacologically inactive main metabolite, and a simple dosage regimen. Also the results indicate that sertraline is an effective atidepressant in elderly depresed patinets and to comparable efficacy to amitriptylin. Sertraline is indicated for the treatment of obsessions and compulsions in patients with obssesive-compulsive disorder, panic disorder, with or without agoraphobia and posttrauumatic stress disorder. In conclusion, it is concidered that sertraline has a fovourable benefit/risk ratio and represents a therapeutic advance over many currently available antidepressants. the administration of sertraline is likely to improve the quality of life in depressed patients by improving depression, preventing reccurence and decreasing the suicide risk, without many of the risks associated with tricyclic antidepressants.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA